CMI/COMPAS MULTI-YEAR COMPARITIVE ANALYSIS GIVES CRITICAL INSIGHT INTO THE PROMOTIONAL-PREFERENCE EVOLUTION

CMI/COMPAS MULTI-YEAR COMPARITIVE ANALYSIS GIVES CRITICAL INSIGHT INTO THE PROMOTIONAL-PREFERENCE EVOLUTION

November 12, 2012

KING OF PRUSSIA, PA – November 12, 2012 – Preferences have evolved for primary care physicians (PCPs) according to the results of a multi-year comparative analysis released today with critical commentary by CMI/Compas. The multi-year comparative study used CMI/Compas proprietary ByDoctor® OnDemand™ promotional response data going back to 2009, concluding that as sales forces dwindle, it's exponentially important for Pharma to engage with PCPs based on their growing multi-channel affinity.

"At a time when physician access is increasingly important, one thing is black and white: doctors want a relationship with Pharma, with a growing affinity for non-personal contact to stay informed and engaged," said Dr. Susan Dorfman, Chief Marketing & Innovation Officer, who contributed to the research.

For more information about this ongoing study or for a copy of the report, please contact:

Reporters: Carly Kuper, VP Corporate Communications at [email protected]

Industry: Lindsay Dinan, New Business Support Manager at [email protected]

About CMI/Compas

Well-known as a media planning and buying organization for healthcare clients, sister agencies Communications Media, Inc. (CMI) and Compas, Inc. together form the indispensable strategic marketing partner to the world's game-changers in health, offering guidance at every level of marketing. CMI/Compas focuses on core service offerings of Media, Innovation, Customer Insights, Technology, and Buying. CMI/Compas is laser-focused on helping clients move the promotional needle. CMI/Compas has offices in Philadelphia; King of Prussia, PA; Pennsauken, NJ; and New York. The family of companies is actively recruiting for healthcare marketing jobs via http://www.cmirecruiter.com

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.